Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Vulvar Neoplasms × cemiplimab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 20 Squamous Cell Carcinoma of Head and Neck 7 Lung Neoplasms 7 Neoplasms 6 Melanoma 6 Carcinoma, Squamous Cell 5 Skin Neoplasms 4 Carcinoma, Renal Cell 4 Urinary Bladder Neoplasms 3 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Carcinoma 3 Breast Neoplasms 3 Adenocarcinoma 3 Rectal Neoplasms 2 Pancreatic Neoplasms 2 Oropharyngeal Neoplasms 2 Neoplasm Metastasis 2 Mesothelioma, Malignant 2 Carcinoma, Merkel Cell 2 Carcinoma, Hepatocellular 2 Carcinoma, Basal Cell 2 Adrenocortical Carcinoma 2 Vulvar Neoplasms 1 Vaccinia 1 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Solid Tumors 1 Small Cell Lung Carcinoma 1

Interventions

pembrolizumab 5 Cisplatin 4 Radiotherapy 3 Nivolumab 3 lenvatinib 2 Specimen Handling 2 Platinum 2 Papillomavirus Vaccines 2 Paclitaxel 2 Ipilimumab 2 Gemcitabine 2 Carboplatin 2 CTLA-4 Antigen 2 Bleomycin 2 Bevacizumab 2 1,2-diaminocyclohexaneplatinum II citrate 2 zimberelimab 1 liposomal doxorubicin 1 dostarlimab 1 cemiplimab 1 belzutifan 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alovudine 1 Watchful Waiting 1 Vorinostat 1 Vaccines, Synthetic 1 Vaccines 1 Ritonavir 1 Radiotherapy, Intensity-Modulated 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07101848 2025-08-03

BRAVA VULVAR

Hospital Israelita Albert Einstein

Phase 2 Not yet recruiting

Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡